Name: sincalide
Brand: KINEVAC

What is the patent landscape for Kinevac, and when can generic versions of Kinevac launch?

Kinevac is a drug marketed by Bracco and is included in one NDA. There is one patent protecting this drug.

This drug has ten patent family members in eight countries.

The generic ingredient in KINEVAC is sincalide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sincalide profile page.

Summary for Tradename: KINEVAC

Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers: see list	1
Bulk Api Vendors: see list	17
Clinical Trials: see list	1
Patent Applications: see list	286
Drug Prices:	see details
DailyMed Link:	KINEVAC at DailyMed

Pharmacology for Tradename: KINEVAC

Ingredient-type	Cholecystokinin
Drug Class	Cholecystokinin Analog

ADD ALERT

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	RS	Patent No.	Patent Expiration	Product	Exclusivity Expiration
Bracco	KINEVAC	sincalide	INJECTABLE;INJECTION	017697-001	Approved Prior to Jan 1, 1982	RX	Yes	Yes	► Subscribe	► Subscribe	Y	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: KINEVAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	KINEVAC	sincalide	INJECTABLE;INJECTION	017697-001	Approved Prior to Jan 1, 1982	► Subscribe	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: KINEVAC

Country	Document Number	Estimated Expiration
China	100374154	► Subscribe
Austria	502647	► Subscribe
China	1756557	► Subscribe
Japan	2006515321	► Subscribe
European Patent Office	1631305	► Subscribe
Germany	60336509	► Subscribe
World Intellectual Property Organization (WIPO)	2005027954	► Subscribe
Japan	4751993	► Subscribe
Australia	2003304382	► Subscribe
Canada	2503982	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Make Better Decisions

DrugPatentWatch Database Preview

KINEVAC Drug Profile

« Back to Dashboard